'Gender gap' in multiple sclerosis: Magnetic resonance imaging evidence

European Journal of Neurology

Volumn 10, Issue 1, 2003, Pages 95-97

  Pozzilli, Carlo ^a   Tomassini, V ^a   Marinelli, F ^a   Paolillo, A ^a   Gasperini, C ^b   Bastianello, S ^a  

^a SAPIENZA UNIVERSITY OF ROME   (Italy)

^b SAN CAMILLO FORLANINI HOSPITAL   (Italy)

Author keywords

Gender difference; Magnetic resonance imaging; Multiple sclerosis

Indexed keywords

ADULT; ARTICLE; CALCULATION; CONTRAST ENHANCEMENT; CONTROLLED STUDY; DISEASE PREDISPOSITION; FEMALE; HISTOPATHOLOGY; HUMAN; MAJOR CLINICAL STUDY; MALE; MULTIPLE SCLEROSIS; NUCLEAR MAGNETIC RESONANCE IMAGING; PRIORITY JOURNAL; SEX DIFFERENCE;

ADULT; CHI-SQUARE DISTRIBUTION; COHORT STUDIES; CROSS-SECTIONAL STUDIES; FEMALE; HUMANS; MAGNETIC RESONANCE IMAGING; MALE; MIDDLE AGED; MULTIPLE SCLEROSIS; SEX CHARACTERISTICS; STATISTICS, NONPARAMETRIC;

EID: 0037238049     PISSN: 13515101     EISSN: None     Source Type: Journal    
DOI: 10.1046/j.1468-1331.2003.00519.x     Document Type: Article

References (11)

1. Benson PB (1994). Age and sex associations of 40 autoimmune diseases. Am J Med 96:457-465.
2. Hawkins SA, McDonnell GV (1999). Benign multiple sclerosis? Clinical course, long term follow-up and assessment of prognostic factors. J Neurol Neurosurg Psychiatry 67:148-152.
3. Koudriavtseva T, Thompson AJ, Fiorelli M et al. (1997). Gadolinium enhanced MRI predicts clinical and MRI disease activity in relapsing-remitting multiple sclerosis. J Neurol Neurosurg Psychiatry 62:285-287.
4. Li DK, Zhao GJ, Paty DW, The University of British Columbia MS/MRI Analysis Research Group. The SPEC-TRIMS Study Group. (2001). Randomized controlled trial of Interferon beta-1a in secondary progressive MS: MRI results. Neurology 56:1505-1513.
5. Molyneux PD, Filippi M, Barkhof F et al. (1998). Correlation between monthly enhanced MRI lesion rate and changes in T2 lesion volume in multiple sclerosis. Ann Neurol 43:332-339.
6. Secondary Progressive Efficacy Clinical Trial of Recombinant Interferon beta-1a in MS, (SPECTRIMS) Study Group. (2001). Randomized controlled trial of Interferon beta-1a in secondary progressive MS: clinical results. Neurology 56:1496-1504.
7. Stein DG (2001). Brain damage, sex hormones and recovery: a new role for progesterone and estrogen? Trends Neurosci 24:386-391.
8. Stevenson VL, Miller DH, Leary SM et al. (2000). One-year follow-up study of primary and transitional progressive multiple sclerosis. J Neurol Neurosurg Psychiatry 68:713-718.
9. Truyen L, van Waesberghe JH, van Walderveen MA et al. (1996). Accumulation of hypointense lesions ('black holes') on T1 spin-echo MRI correlates with disease progression in multiple sclerosis. Neurology 47:1469-1476.
10. van Walderveen MA, Lycklama A, Nijeholt GJ et al. (2001). Hypointense lesions on T1-weighted spino-echo magnetic resonance imaging: relation to clinical characteristics in subgroups of patients with Multiple Sclerosis. Arch Neurol 58:76-81.
11. van Walderveen MA, Truyen L, van Oosten BW et al. (1999). Development of hypointense lesions on T1-weighted spino-echo magnetic resonance images in MS. Arch Neurol 56:345-351.